Kathryn Colborn
Concepts (460)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 14 | 2025 | 1177 | 3.970 |
Why?
| | Postoperative Complications | 34 | 2026 | 2920 | 2.980 |
Why?
| | Machine Learning | 11 | 2026 | 587 | 2.290 |
Why?
| | Surgical Wound Infection | 8 | 2025 | 316 | 1.870 |
Why?
| | Models, Statistical | 6 | 2026 | 682 | 1.590 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 203 | 1.340 |
Why?
| | Sepsis | 7 | 2025 | 641 | 1.340 |
Why?
| | Surgical Procedures, Operative | 6 | 2025 | 271 | 1.330 |
Why?
| | Shock, Septic | 5 | 2025 | 216 | 1.310 |
Why?
| | Pancreatic Neoplasms | 11 | 2025 | 927 | 1.210 |
Why?
| | Quality Improvement | 14 | 2023 | 1291 | 1.160 |
Why?
| | Malaria | 4 | 2023 | 73 | 1.000 |
Why?
| | Law Enforcement | 1 | 2025 | 48 | 0.900 |
Why?
| | Retrospective Studies | 51 | 2026 | 17101 | 0.900 |
Why?
| | Police | 1 | 2025 | 45 | 0.900 |
Why?
| | Quality of Life | 13 | 2026 | 3192 | 0.860 |
Why?
| | Humans | 139 | 2026 | 144957 | 0.850 |
Why?
| | Databases, Factual | 16 | 2025 | 1486 | 0.740 |
Why?
| | Risk Assessment | 20 | 2026 | 3676 | 0.730 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 104 | 0.730 |
Why?
| | Pneumonia | 4 | 2025 | 631 | 0.720 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 33 | 0.710 |
Why?
| | Palliative Care | 10 | 2026 | 1008 | 0.690 |
Why?
| | Emergency Service, Hospital | 5 | 2025 | 2313 | 0.690 |
Why?
| | Pain | 2 | 2023 | 782 | 0.650 |
Why?
| | Plasmodium vivax | 2 | 2018 | 6 | 0.650 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.650 |
Why?
| | Middle Aged | 46 | 2026 | 35928 | 0.620 |
Why?
| | Adenocarcinoma | 5 | 2024 | 931 | 0.610 |
Why?
| | Aged | 38 | 2026 | 25947 | 0.610 |
Why?
| | Female | 68 | 2026 | 78376 | 0.610 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 489 | 0.580 |
Why?
| | Preoperative Care | 5 | 2026 | 380 | 0.580 |
Why?
| | Male | 61 | 2026 | 72406 | 0.580 |
Why?
| | Surgeons | 4 | 2025 | 340 | 0.560 |
Why?
| | Artificial Intelligence | 1 | 2023 | 367 | 0.550 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2456 | 0.550 |
Why?
| | Inpatients | 4 | 2023 | 546 | 0.550 |
Why?
| | Poisson Distribution | 1 | 2018 | 78 | 0.540 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 39 | 0.530 |
Why?
| | Thoracic Surgery | 3 | 2025 | 144 | 0.530 |
Why?
| | Health Plan Implementation | 1 | 2019 | 136 | 0.530 |
Why?
| | Risk Factors | 26 | 2026 | 10792 | 0.510 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 463 | 0.510 |
Why?
| | Mosquito Control | 2 | 2023 | 29 | 0.490 |
Why?
| | Hospitalization | 7 | 2025 | 2434 | 0.490 |
Why?
| | Adult | 41 | 2025 | 40506 | 0.490 |
Why?
| | Algorithms | 5 | 2025 | 1839 | 0.470 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.460 |
Why?
| | Child, Preschool | 19 | 2026 | 11799 | 0.450 |
Why?
| | Anopheles | 1 | 2015 | 17 | 0.450 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 292 | 0.440 |
Why?
| | Drug Prescriptions | 3 | 2021 | 285 | 0.410 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 383 | 0.410 |
Why?
| | Risk Adjustment | 2 | 2025 | 85 | 0.410 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 94 | 0.380 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 108 | 0.370 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 80 | 0.370 |
Why?
| | Primary Health Care | 3 | 2025 | 1734 | 0.360 |
Why?
| | Patient Discharge | 2 | 2020 | 983 | 0.360 |
Why?
| | Hospital Mortality | 1 | 2016 | 1031 | 0.350 |
Why?
| | Decision Support Systems, Clinical | 2 | 2026 | 265 | 0.340 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 182 | 0.330 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 113 | 0.330 |
Why?
| | Infant | 14 | 2026 | 10039 | 0.330 |
Why?
| | Mastectomy | 4 | 2024 | 162 | 0.330 |
Why?
| | Influenza, Human | 3 | 2021 | 617 | 0.320 |
Why?
| | Incidence | 8 | 2023 | 2883 | 0.310 |
Why?
| | Hospitals | 4 | 2025 | 732 | 0.310 |
Why?
| | Emergency Treatment | 2 | 2021 | 124 | 0.300 |
Why?
| | Zebrafish | 2 | 2025 | 528 | 0.300 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 601 | 0.300 |
Why?
| | Pancreatectomy | 4 | 2025 | 285 | 0.300 |
Why?
| | Heart Failure | 5 | 2025 | 2323 | 0.290 |
Why?
| | Colorado | 9 | 2025 | 4564 | 0.290 |
Why?
| | United States | 20 | 2025 | 15988 | 0.280 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8279 | 0.280 |
Why?
| | Research Design | 3 | 2022 | 1137 | 0.270 |
Why?
| | Cohort Studies | 11 | 2024 | 5965 | 0.270 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.260 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 279 | 0.260 |
Why?
| | Adolescent | 16 | 2026 | 22453 | 0.260 |
Why?
| | Logistic Models | 5 | 2023 | 2119 | 0.260 |
Why?
| | Preoperative Period | 2 | 2025 | 149 | 0.250 |
Why?
| | Chagas Disease | 2 | 2018 | 42 | 0.250 |
Why?
| | Asthma | 1 | 2019 | 1768 | 0.250 |
Why?
| | Patient Satisfaction | 4 | 2024 | 705 | 0.250 |
Why?
| | Seasons | 3 | 2025 | 556 | 0.250 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 609 | 0.250 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1325 | 0.250 |
Why?
| | Child | 16 | 2026 | 22657 | 0.250 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 412 | 0.250 |
Why?
| | Prognosis | 10 | 2024 | 4293 | 0.250 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.240 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 158 | 0.240 |
Why?
| | Bayes Theorem | 2 | 2026 | 433 | 0.240 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 372 | 0.230 |
Why?
| | Varenicline | 1 | 2025 | 28 | 0.230 |
Why?
| | Markov Chains | 1 | 2026 | 129 | 0.230 |
Why?
| | Monte Carlo Method | 1 | 2026 | 155 | 0.230 |
Why?
| | Survival Analysis | 2 | 2026 | 1385 | 0.230 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.230 |
Why?
| | Intracranial Pressure | 1 | 2026 | 65 | 0.220 |
Why?
| | Time-to-Treatment | 2 | 2025 | 245 | 0.220 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 421 | 0.220 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 201 | 0.220 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 76 | 0.220 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 34 | 0.210 |
Why?
| | Varicose Veins | 1 | 2024 | 16 | 0.210 |
Why?
| | Treatment Outcome | 13 | 2025 | 11695 | 0.210 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 119 | 0.210 |
Why?
| | Artemisinins | 2 | 2023 | 5 | 0.200 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 914 | 0.200 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
| | Specialties, Surgical | 2 | 2021 | 82 | 0.190 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 41 | 0.190 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 311 | 0.190 |
Why?
| | Hypothermia | 1 | 2023 | 52 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1540 | 0.190 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 60 | 0.190 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 36 | 0.190 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2118 | 0.190 |
Why?
| | Insecticides | 1 | 2023 | 42 | 0.190 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 51 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 70 | 0.190 |
Why?
| | Europe | 1 | 2023 | 412 | 0.190 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 71 | 0.190 |
Why?
| | Behavior Therapy | 1 | 2025 | 299 | 0.180 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1143 | 0.180 |
Why?
| | Telemetry | 1 | 2022 | 41 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1358 | 0.180 |
Why?
| | Medication Therapy Management | 1 | 2023 | 73 | 0.180 |
Why?
| | Microcephaly | 1 | 2023 | 103 | 0.180 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 49 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2025 | 284 | 0.180 |
Why?
| | Young Adult | 11 | 2020 | 14126 | 0.180 |
Why?
| | Syncope | 1 | 2022 | 55 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2023 | 102 | 0.180 |
Why?
| | Polypharmacy | 1 | 2023 | 93 | 0.180 |
Why?
| | Anti-Bacterial Agents | 4 | 2025 | 1915 | 0.180 |
Why?
| | Quinolines | 2 | 2023 | 193 | 0.180 |
Why?
| | Hospitals, Pediatric | 1 | 2025 | 557 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 223 | 0.180 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 44 | 0.180 |
Why?
| | Galectins | 1 | 2022 | 27 | 0.180 |
Why?
| | Pneumonectomy | 1 | 2023 | 169 | 0.180 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 90 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 439 | 0.170 |
Why?
| | Ivermectin | 1 | 2021 | 14 | 0.170 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 104 | 0.170 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 114 | 0.170 |
Why?
| | Computer Simulation | 1 | 2026 | 1026 | 0.170 |
Why?
| | Precision Medicine | 1 | 2025 | 458 | 0.170 |
Why?
| | Program Evaluation | 3 | 2021 | 949 | 0.160 |
Why?
| | Dysbiosis | 1 | 2022 | 187 | 0.160 |
Why?
| | Oxycodone | 1 | 2021 | 53 | 0.160 |
Why?
| | New Guinea | 2 | 2018 | 3 | 0.160 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 23 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 340 | 0.160 |
Why?
| | Internet | 1 | 2025 | 700 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 603 | 0.160 |
Why?
| | Communication | 2 | 2025 | 967 | 0.160 |
Why?
| | Knee Joint | 2 | 2021 | 426 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2022 | 125 | 0.160 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 717 | 0.160 |
Why?
| | Arthroplasty | 1 | 2020 | 59 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 252 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 45 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2025 | 1721 | 0.150 |
Why?
| | Faculty | 1 | 2021 | 149 | 0.150 |
Why?
| | Qualitative Research | 2 | 2025 | 1671 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 248 | 0.150 |
Why?
| | Brain Injuries, Traumatic | 1 | 2026 | 441 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 3164 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1958 | 0.150 |
Why?
| | Antimalarials | 1 | 2019 | 35 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 282 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 142 | 0.150 |
Why?
| | Telemedicine | 2 | 2025 | 948 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 242 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 71 | 0.150 |
Why?
| | Waiting Lists | 2 | 2021 | 263 | 0.150 |
Why?
| | Prisons | 1 | 2010 | 84 | 0.150 |
Why?
| | Intensive Care Units | 2 | 2022 | 916 | 0.140 |
Why?
| | Vaccination | 2 | 2025 | 1423 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.140 |
Why?
| | Laparoscopy | 1 | 2023 | 475 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 224 | 0.140 |
Why?
| | Organ Transplantation | 1 | 2021 | 248 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 324 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2019 | 122 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1563 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 207 | 0.140 |
Why?
| | Healthcare Disparities | 3 | 2025 | 728 | 0.140 |
Why?
| | Social Marketing | 1 | 2008 | 16 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 886 | 0.140 |
Why?
| | Prospective Studies | 7 | 2026 | 7997 | 0.140 |
Why?
| | Hospitals, University | 1 | 2018 | 176 | 0.140 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 39 | 0.140 |
Why?
| | Ventricular Function | 1 | 2018 | 57 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.140 |
Why?
| | General Surgery | 1 | 2021 | 207 | 0.140 |
Why?
| | Outpatients | 1 | 2022 | 443 | 0.140 |
Why?
| | Triage | 1 | 2021 | 249 | 0.140 |
Why?
| | Community Participation | 1 | 2019 | 132 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2022 | 281 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 439 | 0.140 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 382 | 0.140 |
Why?
| | Rural Population | 2 | 2020 | 650 | 0.140 |
Why?
| | Computers, Handheld | 1 | 2018 | 26 | 0.140 |
Why?
| | Reproductive Medicine | 1 | 2008 | 17 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 176 | 0.130 |
Why?
| | Autistic Disorder | 1 | 2020 | 211 | 0.130 |
Why?
| | Population Groups | 1 | 2018 | 58 | 0.130 |
Why?
| | Climate | 1 | 2018 | 89 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1269 | 0.130 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 46 | 0.130 |
Why?
| | Geography | 1 | 2018 | 203 | 0.130 |
Why?
| | Condoms | 1 | 2008 | 101 | 0.130 |
Why?
| | Patient Admission | 1 | 2019 | 218 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 101 | 0.130 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 118 | 0.130 |
Why?
| | Immunoglobulin A | 1 | 2019 | 214 | 0.130 |
Why?
| | ROC Curve | 1 | 2019 | 615 | 0.130 |
Why?
| | Safety-net Providers | 1 | 2019 | 126 | 0.130 |
Why?
| | Burns | 1 | 2022 | 377 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.130 |
Why?
| | Recovery of Function | 1 | 2021 | 710 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 338 | 0.130 |
Why?
| | Occupational Health | 1 | 2010 | 209 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2023 | 173 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2017 | 63 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 98 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 128 | 0.130 |
Why?
| | Cell Phone | 1 | 2017 | 82 | 0.120 |
Why?
| | Anxiety Disorders | 1 | 2010 | 373 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2021 | 529 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 74 | 0.120 |
Why?
| | HIV Infections | 2 | 2025 | 3154 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 375 | 0.120 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 496 | 0.120 |
Why?
| | Parents | 1 | 2025 | 1403 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 103 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2010 | 354 | 0.120 |
Why?
| | Fever | 1 | 2017 | 312 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 391 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 759 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 761 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 817 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 144 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2018 | 140 | 0.120 |
Why?
| | Morbidity | 3 | 2022 | 323 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5417 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2025 | 1158 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 847 | 0.110 |
Why?
| | Humidity | 1 | 2015 | 52 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 893 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 196 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 672 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 192 | 0.110 |
Why?
| | Mass Screening | 2 | 2020 | 1348 | 0.110 |
Why?
| | Massage | 2 | 2010 | 42 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 404 | 0.110 |
Why?
| | Cannabidiol | 1 | 2016 | 136 | 0.110 |
Why?
| | Advance Care Planning | 1 | 2018 | 243 | 0.100 |
Why?
| | Pandemics | 4 | 2025 | 1695 | 0.100 |
Why?
| | Anticonvulsants | 1 | 2016 | 242 | 0.100 |
Why?
| | Time Factors | 5 | 2024 | 7183 | 0.100 |
Why?
| | Stroke | 1 | 2023 | 1258 | 0.100 |
Why?
| | Neoplasms | 2 | 2025 | 2884 | 0.100 |
Why?
| | Survival Rate | 3 | 2024 | 2092 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1990 | 0.100 |
Why?
| | Parasitemia | 1 | 2013 | 15 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1822 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2021 | 696 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 550 | 0.100 |
Why?
| | Indians, North American | 1 | 2009 | 647 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 590 | 0.100 |
Why?
| | Research | 1 | 2016 | 431 | 0.100 |
Why?
| | Chronic Pain | 1 | 2018 | 292 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1209 | 0.090 |
Why?
| | Medicaid | 1 | 2017 | 462 | 0.090 |
Why?
| | Software | 1 | 2018 | 692 | 0.090 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 567 | 0.090 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6053 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 108 | 0.090 |
Why?
| | Axilla | 2 | 2023 | 51 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 679 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 176 | 0.090 |
Why?
| | Washington | 2 | 2025 | 147 | 0.090 |
Why?
| | Epilepsy | 1 | 2016 | 387 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 181 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 405 | 0.090 |
Why?
| | Patients | 2 | 2023 | 182 | 0.090 |
Why?
| | Uganda | 2 | 2023 | 93 | 0.080 |
Why?
| | Age Factors | 4 | 2021 | 3335 | 0.080 |
Why?
| | Prevalence | 3 | 2023 | 2836 | 0.080 |
Why?
| | Pain Management | 2 | 2010 | 405 | 0.080 |
Why?
| | Disease Progression | 1 | 2019 | 2852 | 0.080 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 334 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2925 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 2025 | 1465 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2017 | 736 | 0.080 |
Why?
| | Internship and Residency | 1 | 2021 | 1257 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 354 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2197 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2642 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.070 |
Why?
| | Guatemala | 2 | 2023 | 345 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 887 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2015 | 685 | 0.070 |
Why?
| | Administration, Oral | 2 | 2025 | 848 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2023 | 502 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 888 | 0.070 |
Why?
| | Piperazines | 2 | 2023 | 381 | 0.070 |
Why?
| | Biomedical Research | 2 | 2025 | 710 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 589 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 194 | 0.060 |
Why?
| | Echocardiography | 2 | 2022 | 652 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1660 | 0.060 |
Why?
| | Urban Population | 2 | 2020 | 491 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 224 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 239 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2023 | 853 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1337 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 21 | 0.060 |
Why?
| | Affect | 1 | 2008 | 318 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
| | India | 1 | 2025 | 218 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1890 | 0.060 |
Why?
| | Administration, Intravenous | 1 | 2025 | 170 | 0.050 |
Why?
| | Glasgow Coma Scale | 1 | 2026 | 213 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2065 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2022 | 6434 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1327 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 1031 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 367 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5872 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 539 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2438 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2026 | 289 | 0.050 |
Why?
| | Animals | 4 | 2025 | 38109 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 222 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 121 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 17 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2023 | 133 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 23 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 86 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 74 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 85 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 20 | 0.050 |
Why?
| | Death | 1 | 2023 | 131 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 636 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 35 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 10 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 130 | 0.050 |
Why?
| | Breast | 1 | 2023 | 159 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 48 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 881 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 87 | 0.050 |
Why?
| | Cough | 1 | 2023 | 124 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 353 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 651 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2023 | 207 | 0.040 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.040 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 104 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2023 | 769 | 0.040 |
Why?
| | Demography | 1 | 2022 | 288 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 467 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 202 | 0.040 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 64 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 123 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 674 | 0.040 |
Why?
| | Habits | 1 | 2020 | 52 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 239 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 186 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 161 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 573 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 35 | 0.040 |
Why?
| | Policy | 1 | 2021 | 147 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4109 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 157 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1268 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 249 | 0.040 |
Why?
| | Fear | 1 | 2023 | 366 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 261 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 521 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 631 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 249 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 50 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 15 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2022 | 911 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 66 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 370 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 219 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 101 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 529 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 509 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 129 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 5 | 0.030 |
Why?
| | Colombia | 1 | 2018 | 42 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 520 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2010 | 268 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 157 | 0.030 |
Why?
| | Fluorouracil | 1 | 2019 | 235 | 0.030 |
Why?
| | Drug Combinations | 1 | 2019 | 392 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 259 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2023 | 544 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 424 | 0.030 |
Why?
| | Overweight | 1 | 2023 | 609 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1813 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 180 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1322 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 141 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1077 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 582 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 376 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 6 | 0.030 |
Why?
| | Caregivers | 1 | 2025 | 1049 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 526 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 94 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1141 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 892 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 143 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 792 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 837 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 357 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 485 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 129 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 289 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 166 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1110 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 836 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 151 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 389 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 187 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 663 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 566 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 854 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1742 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 303 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 4099 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1060 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 809 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3608 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3415 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2114 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 774 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4275 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2880 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3082 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2385 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 312 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1603 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 1099 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|